Macrocytic anemia pathophysiology

Revision as of 23:27, 18 August 2018 by Amandeep Singh (talk | contribs)
Jump to navigation Jump to search

Macrocytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Macrocytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Macrocytic anemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Macrocytic anemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Macrocytic anemia pathophysiology

CDC on Macrocytic anemia pathophysiology

Macrocytic anemia pathophysiology in the news

Blogs on Macrocytic anemia pathophysiology

Directions to Hospitals Treating Macrocytic anemia

Risk calculators and risk factors for Macrocytic anemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology

Biochemical Review

  • Folate is important in the production of various building blocks necessary for the production of biologic macromolecules. By combining with carbon moieties, tetrahydrofolate (THF) becomes methelenetetrahydofolate. This molecule is then able to donate carbon moieties to form purines, dTMP, and methionine. Of note, Vitamin B12 is also a cofactor in the production of methionine.
  • THF is the resulting molecule after donation of carbon moieties except in the synthesis of dTMP from dUMP. DHF (dihydrofolate) results from this reaction. DHF reductase must act on DHF to participate in reactions again.
  • The two metabolically active forms of Vitamin B12 are Methycobalamin and Adenosylcobalamin. The former is important in methionine synthesis. Methionine is necessary for the production of choline phospholipids. Adenosylcobalamin is necessary to convert methylmalonyl CoA to succinyl-CoA. Interruption of this reaction eventually leads to nonphysiologic fatty acid production and abnormal neuronal lipid production.
  • B12 deficiency also leads to folate metabolism derangement. Tissue folate levels are reduced in the setting of Vitamin B12 deficiency through a complicated biochemical pathway. This is known as the “folate trap hypothesis” and explains why large doses of folate will help the hematological manifestations. The mechanism of the neurologic manifestations remains independent of folate metabolism.

Body Stores

Folate

  • Folate has minimum daily requirement of 50 mcg per day this requirement can increase substantially in settings such as pregnancy.
  • Total body stores are approximately 5-20mg with half held in the liver. The serum folate level is not a reliable index of tissue folate levels.
  • Serum folate levels can go up or down despite normal tissue levels depending on dietary intake and EtOH intake. The RBC (red blood cell) folate level is a better measure of tissue folate stores.

Vitamin B12

  • The minimum daily requirement for B12 is 2.5 mcg.
  • About 4mg is stored in the body with half in the liver.
  • Obviously, it takes much longer to become B12 (3-6 years) versus folate (3 months) if intake ceased abruptly.
  • The test for B12 is variable.


<imagemap> Image:Normal RBC.jpg|240px|thumb|Normal human red blood cells appear as concave disks with a zone of central pallor that typically occupies 30% of the total size. There is minimal variation in size and shape between individual red blood cells. </imagemap>

<imagemap> Image:Macrocytosis.jpg|230px|thumb|Non-megaloblastic macrocytosis is characterized by the presence of large RBCs (macrocytes). It is difficult to appreciate the increased size on an individual peripheral smear. </imagemap>

<imagemap> Image:Hypersegmented neutrophil.png|thumb|Megaloblastic macrocytosis is characterized by the presence of large RBCs (macrocytes) and hypersegmented neutrophils ≥ 5 lobes (red arrow). </imagemap>

Associated Conditions

Gross Pathology

  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Microscopic Pathology

  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

<imagemap> Image:Normal RBC.jpg|240px|thumb|Normal human red blood cells appear as concave disks with a zone of central pallor that typically occupies 30% of the total size. There is minimal variation in size and shape between individual red blood cells. </imagemap>

<imagemap> Image:Macrocytosis.jpg|230px|thumb|Non-megaloblastic macrocytosis is characterized by the presence of large RBCs (macrocytes). It is difficult to appreciate the increased size on an individual peripheral smear. </imagemap>

<imagemap> Image:Hypersegmented neutrophil.png|thumb|Megaloblastic macrocytosis is characterized by the presence of large RBCs (macrocytes) and hypersegmented neutrophils ≥ 5 lobes (red arrow). </imagemap>

References

Template:WikiDoc Sources